GAM
IGMS

Grandview Asset Management’s IGM Biosciences IGMS Stock Holding History

Grandview Asset Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-61
Closed -$5K – 258
2021
Q1 		$5K Buy
+61
New +$5.55K ﹤0.01% 387

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Grandview Asset Management's IGMS Position: Q2 2021 in Review

Grandview Asset Management sold out of IGM Biosciences (IGMS) in Q2 2021, closing a stake of 61 shares — an estimated $5K sold.

Grandview Asset Management first reported a position in IGMS in Q1 2021 and held it in 1 quarter. The position peaked at $5K in Q1 2021. 104 funds tracked by Wall St. Rank hold IGMS as of Q2 2021.

  • Grandview Asset Management reported no remaining IGM Biosciences position as of Q2 2021 after selling out during the quarter.
  • Grandview Asset Management sold 61 IGM Biosciences shares in Q2 2021, an estimated $5K.
  • Grandview Asset Management first reported a position in IGM Biosciences in Q1 2021 and held it in 1 quarter.
  • Grandview Asset Management's IGM Biosciences position peaked at $5K in Q1 2021.
  • 104 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2021.

Based on Grandview Asset Management's 13F filing for Q2 2021, filed 21 Jul 2021.